Topical skin formulations of pharmaceutically acceptable salts of ruxolitinib

By adding a pharmaceutically acceptable acid to ruxolitinib cream to form an oil-in-water emulsion, the problem of ruxolitinib dihydrate crystal formation was solved, the stability of the formulation was improved, and it is suitable for the treatment of skin conditions.

CN122161582APending Publication Date: 2026-06-05INCYTE CORP
View PDF 22 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
INCYTE CORP
Filing Date
2025-08-25
Publication Date
2026-06-05

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to topical skin formulations comprising a pharmaceutically acceptable salt of ruxolitinib and uses in the treatment of skin conditions.
Need to check novelty before this filing date? Find Prior Art